Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7447937 | 0.82 | PDE5A (0.47) | PDE5ACA12CA9 | |
| SCHEMBL7430980 | 0.80 | PDE5A (0.45) | PDE5A | |
| SCHEMBL3835987 | 0.73 | PDE5A (0.60) | PDE5ACA12CA9POLB | |
| SCHEMBL974265 | 0.71 | PDE5A (0.64) | PDE5APOLB | |
| SCHEMBL14686004 | 0.66 | PDE5A (0.43) | PDE5A | |
| SCHEMBL4607619 | 0.66 | PDE5A (0.59) | PDE5APOLB | |
| SCHEMBL975296 | 0.66 | PDE5A (0.61) | PDE5APOLB | |
| SCHEMBL975154 | 0.65 | PDE5A (0.58) | PDE5APOLB | |
| SCHEMBL974080 | 0.65 | PDE5A (0.65) | PDE5ACA12CA9POLB | |
| SCHEMBL12070 | 0.64 | PDE5A (0.71) | PDE5APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365806-A2 | USE OF NO ACTTIVATORS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-03 | — | — | EP | claimed |
| EP-0793498-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 2002-12-11 | — | — | EP | claimed |
| WO-2001078781-A9 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | UNIV JOHNS HOPKINS (US) | 2002-07-25 | — | — | WO | claimed |
| WO-2001078781-A2 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2001-10-25 | — | — | WO | claimed |
| WO-1993006104-A1 | PYRAZOLOPYRIMIDINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-04-01 | — | — | WO | claimed |
| EP-1365806-A2 | USE OF NO ACTTIVATORS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1331950-A1 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | The Johns Hopkins University (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2001078781-A9 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | UNIV JOHNS HOPKINS (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002030470-A1 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | JOHNS HOPKINS UNIVERSITY (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001078781-A2 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-1140044-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037061-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| EP-0793498-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016657-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |